Xenith Biomed develops E coli 157:H7 test:
This article was originally published in Clinica
Xenith Biomed has begun selling an E coli 157:H7 variant diagnostic system, devised in conjunction with Ireland's National Diagnostic Centre. The Centre has developed an enzyme immunoassay EIA microtitre format, while Rosaveal, County Galway-based Xenith has developed a lateral flow device quick test. Samples require a 16-hour culture before detection using the combined system.
You may also be interested in...
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”
CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.